Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METATENSIN #2 vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Reserpine: primarily metabolized by CYP3A4; methyclothiazide: not extensively metabolized, excreted unchanged in urine.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
85% bound to albumin and alpha-1-acid glycoprotein
Approximately 70-80% bound to plasma proteins, primarily albumin.
2.5 L/kg; indicates extensive tissue distribution
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 60% (first-pass metabolism reduces bioavailability)
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-60 m L/min, reduce dose by 50%; avoid if possible. Monitor potassium and creatinine.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B, use with caution; reduce dose by 50% and monitor liver function.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not recommended for children; safety and efficacy not established. Use alternative antihypertensives.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start at half the standard dose (0.5-1 tablet every 12 hours). Monitor for hypotension, electrolyte imbalance, and CNS effects (depression, sedation). Avoid in frail elderly.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
No FDA black box warning.
None.
Mental depression,Electrolyte imbalance (hypokalemia, hyponatremia),Orthostatic hypotension,Increased gastric acid secretion,Pancreatitis,Exacerbation of systemic lupus erythematosus
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
History of mental depression (especially with suicidal tendencies),Active peptic ulcer,Ulcerative colitis,Electroshock therapy,Hypersensitivity to reserpine, methyclothiazide, or sulfonamides,Anuria
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid high-potassium foods (bananas, oranges, leafy greens) as hydrochlorothiazide can cause hypokalemia; monitor potassium levels. Use salt substitutes cautiously due to potassium content. Avoid excessive sodium intake which may counteract antihypertensive effects. Grapefruit juice may reduce methyldopa absorption; separate by 2 hours.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: Increased risk of cardiovascular and neural tube defects due to inhibition of folate-dependent enzymes. Second and third trimesters: Fetal bradycardia, oligohydramnios, intrauterine growth restriction, and neonatal hypotension. Avoid throughout pregnancy unless maternal benefit outweighs risks.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Excreted into breast milk; M/P ratio approximately 0.8. Potential for neonatal cardiovascular effects such as bradycardia and hypotension. Caution advised; monitor infant for signs of β-blockade.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Increased volume of distribution and renal clearance in pregnancy may necessitate dose escalation. Start at lowest effective dose, titrate based on blood pressure response. Monitor for hypotension and adjust accordingly.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
METATENSIN #2 is a fixed-dose combination of methyldopa and hydrochlorothiazide. Monitor for hypotension, especially during initial dosing. LFTs and CBC at baseline and periodically due to methyldopa's risk of hepatotoxicity and hemolytic anemia. Use with caution in renal impairment (Cr Cl <30 m L/min). Discontinue if jaundice occurs. Adjust dose in hepatic disease.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed at the same time each day.,May cause dizziness or drowsiness; avoid driving until effects are known.,Rise slowly from sitting or lying to prevent lightheadedness.,Report jaundice, fever, unexplained bruising/bleeding, or severe fatigue.,Use sun protection; hydrochlorothiazide increases photosensitivity.,Avoid alcohol, as it may worsen hypotension.,Do not stop abruptly; withdrawal can cause severe hypertension.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METATENSIN #2 vs ALDOCLOR-150, answered by our medical review team.
METATENSIN #2 is a Antihypertensive Combination that works by METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METATENSIN #2 and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METATENSIN #2 is: 1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METATENSIN #2 and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METATENSIN #2 is classified as Category C. First trimester: Increased risk of cardiovascular and neural tube defects due to inhibition of folate-dependent enzymes. Second and third trimesters: Fetal bradycardia, oligohydram. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.